Class
Ghrelin-receptor agonist / GH secretagogue
Pentapeptide; also NNC 26-0161
Protokol listesine dön
Topluluk verisiFDA onayı yok
Topluluk protokolü · Ipamorelin
Ipamorelin: topluluk bilgisi ve kanıt ayrı sunulur.
Yaygın iddiaların hesaplamalar, güvenlik sınırları, klinik kanıt ve güncel düzenleyici bağlamla özgün özeti.
Kaynak kontrolü: 27 Ağustos 2026
Önemli güvenlik ve sorumluluk bildirimi
Bu sayfa çevrimiçi topluluk bilgisini belgeler ve değerlendirir. Tıbbi/terapötik tavsiye, kişisel danışmanlık veya kullanım çağrısı değildir.
- All amounts, schedules, cycles and combinations are unverified community information, not clinically validated dosing.
- Reconstitution and U-100 values are arithmetic only. They do not confirm identity, purity, sterility, stability, suitability or a safe route.
- Information is provided without warranty and any use is at the reader's own risk. To the extent permitted by law, no liability is accepted for miscalculation, use, contamination, interactions or consequences.
- Symptoms, medical conditions, medicines, pregnancy and anti-doping obligations require qualified professional advice.
Hızlı bağlam
Hızlı bağlam
Human PK
about 2-hour terminal half-life
Intravenous phase-I data; mean GH peak around 40 minutes
Approval
No FDA approval
No approved dose for the community goals described
Anti-doping
WADA: prohibited at all times
S2.2.4 growth-hormone releasing factors
Published evidence
Human studies show short pharmacokinetics and GH release after intravenous administration. They do not establish an approved subcutaneous dose or benefits for anti-ageing, muscle gain, fat loss, sleep or recovery.
Community documentation
The schedules below come from the reference page and commonly circulated community models. They have not been confirmed in controlled trials for these goals.
Topluluk verisi
Topluluk miktarları, zamanlama ve döngüler
The reference presents a stepped model. This table records it for context; it is not a starting or escalation plan.
| Community phase | Period | Daily amount | Described timing |
|---|---|---|---|
| Assessment | Week 1 | 100 µg/day | once at bedtime, fasted |
| Titration | Weeks 2–3 | 200 µg/day | once at bedtime or 100 µg AM + 100 µg PM |
| Common model | Weeks 4–8 | 200–300 µg/day | once or twice daily; fasted AM and/or bedtime |
| Extended | Weeks 9–12 | 200–300 µg/day | community continuation if tolerated; sometimes to week 16 |
| Break | 4 weeks | 0 µg | described as an off-cycle |
Not established: no approved schedule supports these subcutaneous amounts, escalation steps, frequencies or breaks. A claimed ceiling around 300 µg and totals up to 900 µg/day are also community claims, not established safety limits.
Described timing
- Community sources commonly place administrations at bedtime or fasted in the morning.
- They often mention 1–2 hours after food and 20–30 minutes before eating; a benefit for these community schedules is not clinically validated.
- One to three times per day are discussed. Missed administrations are generally not doubled in these models.
- Published research has not established separate subcutaneous standard doses for women and men for these goals.
Cycle models
Eight to twelve weeks followed by a four-week break is commonly cited; some models continue to 16 weeks. Neither the benefit and safety of these durations nor claimed receptor recovery during a break has been clinically established.
Daily-total arithmetic only
These examples only multiply amount per administration by frequency. They do not define an appropriate amount.
| Amount each time | Frequency | Calculated daily total |
|---|---|---|
| 100 µg | once daily | 100 µg/day |
| 100 µg | twice daily | 200 µg/day |
| 200 µg | once daily | 200 µg/day |
| 300 µg | three times daily | 900 µg/day |
Topluluk verisi
Sulandırma ve U-100 dönüşümü
The values show only the concentration that would result if the stated vial amount were accurate and the exact fluid volume were added. U-100 means 100 units per 1 ml; one unit is 0.01 ml.
Vial size is not an administration amount
2 mg, 5 mg or 10 mg describes the claimed total amount in the vial. Added fluid changes concentration and volume, not the total micrograms.
| Vial | Fluid | Concentration | 100 µg | 200 µg | 300 µg |
|---|---|---|---|---|---|
| 2 mg | 1.0 ml | 2,000 µg/ml | 0.05 ml / 5 U | 0.10 ml / 10 U | 0.15 ml / 15 U |
| 5 mg | 2.0 ml | 2,500 µg/ml | 0.04 ml / 4 U | 0.08 ml / 8 U | 0.12 ml / 12 U |
| 10 mg | 3.0 ml | 3,333 µg/ml | 0.03 ml / 3 U | 0.06 ml / 6 U | 0.09 ml / 9 U |
Rounded values from the reference. Label, actual volume and syringe scale must be independently verified.
Sulandırma hesaplayıcısı
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Formulas used
- Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
- Volume (ml) = target µg ÷ concentration
- U-100 units = volume ml × 100
Mixing process described by the reference
- 01
Verify inputs
Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.
- 02
Disinfect stoppers
The reference calls for separate alcohol swabs and sterile single-use materials.
- 03
Add fluid slowly
The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.
- 04
Dissolve gently
The vial is rolled or swirled gently, not shaken, until no visible solids remain.
- 05
Inspect visually
Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.
- 06
Label and store by product data
Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.
An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.
Supply arithmetic from the reference
The source models 200 µg daily from a 10-mg vial with 3 ml fluid: about 50 calculated portions per vial, one vial for four weeks and two for 8–12 weeks. This is not medical planning or a recommendation; affiliate offers were excluded.
- At 200 µg per calculated portion, 2/5/10 mg yields a theoretical 10/25/50 portions per vial.
- For 4/8/12 weeks, that is arithmetically 3/6/9 vials of 2 mg, 2/3/4 vials of 5 mg, or 1/2/2 vials of 10 mg.
- 28/56/84 administrations equal 28/56/84 disposable syringes; a 10-ml fluid vial mathematically covers three 3-ml preparations. Losses change the total.
Published evidence
Mekanizma: kanıtlananlar
Ipamorelin is a synthetic pentapeptide and agonist at the ghrelin/growth-hormone secretagogue receptor GHS-R1a. It triggered GH release in preclinical models.
A small phase-I study in healthy men found dose-proportional PK after intravenous infusion, an approximately two-hour terminal half-life and a single GH episode peaking near 0.67 hours.
Claims of selectivity over ACTH/cortisol derive mainly from rat and swine data. They do not establish safety for subcutaneous self-use or long-term exposure.
Target
GHS-R1a / ghrelin receptor
Immediate effect
Pulsatile GH release in studied models
Downstream marker
IGF-1 may change with repeated GH activity
Not established
Anti-ageing, muscle, fat-loss, sleep or recovery benefit
FDA onayı yok
Yan etkiler ve riskler
Community reports and clinical evidence must remain separate. 'Mild' or 'selective' does not mean safe; FDA highlights major data gaps and potential risks for compounded injectable products.
Commonly reported by communities
- headache, fatigue or tingling
- water retention, bloating or joint stiffness
- mild appetite increase
- redness, stinging or a lump at an injection site
FDA-highlighted or plausible risks
- immunogenicity from aggregation or peptide-related impurities
- insufficient safety data for certain injectable routes
- hyperglycaemia and possible impaired glucose tolerance
- in an IV POI study: hypokalaemia, nausea, vomiting, abdominal distension and deaths; causality of the deaths was unclear
Kendi kendine kullanmayın / klinik değerlendirme
There is no validated prescribing standard for these community goals. Particularly high-risk or poorly studied situations include:
- pregnancy, breastfeeding, children and adolescents
- active or recent cancer or an unexplained mass
- diabetes, prediabetes or unstable glucose
- severe heart/kidney disease, oedema or fluid retention
- sleep apnoea or neurological/visual warning signs
- medicines affecting glucose, hormones or fluid balance
- tested sport under anti-doping rules
Warning signs to monitor
- persistent headache or visual change
- rapid swelling, breathlessness or chest pain
- marked glucose increases
- new numbness, wrist pain or worsening sleep-apnoea symptoms
- fever or increasing redness, heat, pain or discharge at an injection site
Acute symptoms
Seek emergency medical care for breathing difficulty, chest pain, altered consciousness, severe allergic reaction, major visual symptoms or signs of serious infection.
Published evidence
İzlem ve laboratuvar değerleri
No established Ipamorelin monitoring standard exists for community use. These items are inferred from GH-axis risk and require professional interpretation, not self-diagnosis.
| Marker / observation | Why it matters | Context |
|---|---|---|
| IGF-1 | Downstream GH-axis marker | Interpret with age and baseline |
| Fasting glucose & HbA1c | Potential insulin-sensitivity changes | Professional baseline and trend review |
| Lipid panel | Metabolic context | Not validated as Ipamorelin-specific monitoring |
| TSH & free T4 | Separate thyroid-related symptoms | Interpret clinically |
| Blood pressure, weight, oedema | Fluid retention and cardiovascular context | Symptoms matter more than one value |
| Sleep-apnoea symptoms | GH-axis stimulation may be problematic | Worsening requires review |
The reference suggests review after about 6–8 weeks and every 3–6 months for longer use. These intervals are not an accepted standard and must never delay urgent care.
Published evidence
Klinik kanıt
Evidence is narrow, addresses different questions and mainly uses intravenous administration. It does not validate the community protocols.
| Source | Design | Result | Limit |
|---|---|---|---|
| Raun et al., 1998 | Preclinical; rats and swine | GH secretagogue with relative selectivity in animals | No human safety or community-dose study |
| Gobburu et al., 1999 | Phase I; 40 healthy men; IV infusion | Dose-proportional PK; t½ ~2 h; GH peak ~40 min | No subcutaneous long-term or benefit protocol |
| Beck et al., 2014 / NCT00672074 | Phase II; 117 bowel-surgery patients; IV | No significant efficacy benefit in postoperative ileus | Different population, indication and route |
| FDA PCAC review, 2024 | Regulatory evidence review | Insufficient SC efficacy/safety data; recommendation against 503A inclusion | Regulatory assessment, not individual risk advice |
Conclusion: pharmacological activity is demonstrated. Clinical efficacy and safety are not established for body composition, anti-ageing, sleep, recovery or the described subcutaneous schedules.
Topluluk verisi
Saklama ve stabilite
Without validated product-specific stability data there is no universal shelf life. The reference lists these community ranges; manufacturer/pharmacy labelling takes priority.
| State | Stated range | Claim / limitation |
|---|---|---|
| Lyophilised powder | −20 °C | source: long term; no universal product confirmation |
| Lyophilised powder | 2–8 °C | source: months; product and packaging dependent |
| Lyophilised powder | room temperature | source: short shipping window/weeks; not a shelf-life guarantee |
| Reconstituted solution | 2–8 °C | source: up to about 28 days; unverified without product data |
| Frozen single-use aliquots | −20 °C | source: 3–4 months; stability/container compatibility unconfirmed |
Protect from light and avoid temperature cycling and repeated freeze-thaw. Discard cloudy, discoloured or particle-containing solutions; a clear solution can still be contaminated or incorrectly constituted.
Sorun giderme ve hatalar
Wrong fluid volume
More fluid changes concentration and ml/U-100 values. Recalculate from the actual volume; do not guess.
Cloudy, coloured or particulate
Do not use. Visible change may indicate instability or contamination.
Unknown vial amount
Correct conversion is impossible without a reliable total. A label or COA does not automatically prove sterility.
Missed time
Community models describe resuming rather than doubling. This is not clinical dosing advice.
Broken cold chain
Remaining shelf life cannot be safely inferred without product stability data. Obtain professional assessment or discard.
Persistent symptoms
Do not solve by further calculation or self-adjustment; pause and seek medical review.
Kaynak kontrolü: 27 Ağustos 2026
Düzenleyici durum ve WADA
FDA approval
Ipamorelin is not FDA-approved for any human use. Clinical testing is not approval.
503A
The earlier 503A nomination was withdrawn in 2024. FDA still reviewed Ipamorelin and the committee recommended against adding it to the 503A bulks list. Removal from an interim category is not authorisation or approval.
503B
Ipamorelin acetate currently remains in FDA Category 2 for 503B compounding, citing potentially significant safety risks including immunogenicity and missing data for certain injectable routes.
WADA 2026
Ipamorelin is expressly listed under S2.2.4 as a GH secretagogue/ghrelin mimetic and is prohibited at all times, in and out of competition.
Other jurisdictions
US compounding categories do not transfer to Switzerland or the EU. Possession, import, supply, use and professional responsibility require current local assessment.
Published evidence
İlgili maddelerle karşılaştırma
This compares targets, evidence and regulatory context; it is not a selection guide.
| Substance | Primary target | Distinction | Status note |
|---|---|---|---|
| Ipamorelin | GHS-R1a | short GH pulse; human PK available | unapproved; WADA-prohibited |
| GHRP-2 / GHRP-6 | GHS-R1a | older secretagogues; stronger ACTH/cortisol or appetite signals in preclinical comparisons | unapproved; WADA-prohibited |
| CJC-1295 / Mod GRF 1-29 | GHRH receptor | different pathway; communities combine both axes | not FDA-approved; WADA-covered |
| Sermorelin | GHRH receptor | GHRH analogue with its own regulatory history | check current local product status |
| Tesamorelin | GHRH receptor | approved for one defined US indication; not interchangeable | FDA approval only for specified HIV lipodystrophy indication |
Kombinasyonlar / stackler
The reference mainly mentions combinations with GHRH analogues. No validated safety or efficacy protocol exists for these community stacks; effects and adverse effects may add up.
- CJC-1295 without DAC (Mod GRF 1-29) plus Ipamorelin is described as a dual-receptor strategy.
- CJC-1295 with DAC has a different duration and must not be treated as identical.
- Tesamorelin and Sermorelin act at the GHRH receptor; approved Tesamorelin data do not validate combination with Ipamorelin.
- BPC-157 is sometimes added in recovery communities, without robust clinical evidence for the combination.
Sık sorulan sorular
Is Ipamorelin an approved medicine?
No. It has no FDA-approved human use or approved dose for the goals discussed here.
Is 2 mg, 5 mg or 10 mg a dose?
No. It is the claimed total vial amount. A single volume also depends on added fluid.
How are U-100 units calculated?
U-100 means 100 units per ml. Calculate concentration from vial amount and fluid, then target amount ÷ concentration × 100.
What community ranges are commonly cited?
The reference describes 100–300 µg per administration, one to three times daily and 8–12-week cycles. These are unvalidated and not recommendations.
Are male and female schedules different?
Published research has not established sex-specific subcutaneous standard dosing for these community goals.
How long does reconstituted material last?
The reference says about 28 days refrigerated. Without product-specific stability data this is not a reliable guarantee.
What tests are discussed?
Mainly IGF-1, fasting glucose/HbA1c, lipids, thyroid markers, fluid retention and sleep-apnoea symptoms. No validated community monitoring standard exists.
Is Ipamorelin permitted in sport?
No. The 2026 WADA List expressly names Ipamorelin and prohibits it at all times.
Does a COA prove safe use?
No. Depending on scope it may describe identity or purity, but does not automatically prove content, sterility, endotoxins, stability or clinical suitability.
Why show the numbers at all?
To make widely circulated claims transparent and place their limitations next to them. Visibility is not endorsement.
Kaynak kontrolü: 27 Ağustos 2026
Kaynaklar ve kanıt sıralaması
Regulatory primary sources and studies support the assessment. The reference page is used only for community schedules; advertising, shops, discount codes and affiliate links were excluded.
Topluluk referansı
Peptide Dosing Protocols — Ipamorelin guide
Source used for the community schedules, calculations, handling claims and FAQ topics; commercial content excluded.
Resmi kaynakFDA — Certain bulk drug substances that may present significant safety risks
Current 503B Category 2 entry and FDA safety concerns for Ipamorelin acetate.
Resmi kaynakFDA PCAC — Ipamorelin-related bulk drug substances review
2024 evidence and safety review, including route-specific gaps and the 503A recommendation.
Resmi kaynakWADA — 2026 Prohibited List
Ipamorelin is listed in S2.2.4 among GH secretagogues and ghrelin mimetics prohibited at all times.
Yayımlanmış çalışmaRaun et al. (1998) — Ipamorelin, the first selective GH secretagogue
Preclinical pharmacological characterisation in rat and swine models.
Yayımlanmış çalışmaGobburu et al. (1999) — Human PK/PD modelling
Phase-I intravenous pharmacokinetics and growth-hormone response in healthy male volunteers.
Yayımlanmış çalışmaBeck et al. (2014) — Phase-II postoperative ileus trial
Randomised IV study in bowel-resection patients; no significant efficacy difference.
Resmi kaynakClinicalTrials.gov — NCT00672074
Official registry record for the completed 117-participant phase-II study.